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Cryptococcal meningitis accounts for 15% of all HIV-
related deaths [1]. The overall number of cryptococcal
meningitis cases has remained relatively stable in many
low-to-middle income countries (LMICs) despite
increasing roll-out of antiretroviral therapy (ART).
Increasing numbers of patients are at risk of developing
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cryptococcal meningitis following ART failure or
discontinuation, offsetting declines in those presenting
for the first time with advanced HIV [2–4]. Over half of
patients diagnosed with cryptococcal meningitis in recent
studies in sub-Saharan Africa are ART-experienced (i.e.
currently receiving or previously received ART) [5,6].
Although there is robust evidence from prospective
randomized trials that ART initiation should be delayed
until 4–6 weeks after starting antifungal therapy in ART-
naı̈ve cryptococcal meningitis patients [7,8], the approach
to ART management among ART-experienced crypto-
coccal meningitis patients lacks adequate evidence, with a
paucity of published data.
We are a group of clinicians and researchers from
AMBIsome Therapy Induction OptimisatioN (AMBI-
TION), a phase III randomized controlled trial exploring
novel treatments for HIV-associated cryptococcal men-
ingitis [9]. In this viewpoint, we aim to synthesize the
existing literature on the management of ART-experi-
enced cryptococcal meningitis patients and present the
consensus that we have reached regarding the optimal
management of these patients, an area where there
remains considerable clinical uncertainty.
ART-experienced cryptococcal meningitis patients are a
heterogenous group. They can be broadly categorized as
those with recent ART initiation (within 6 months);
poor/nonadherence to ART with detectable predomi-
nantly wild-type virus; treatment failure with ART
resistance mutations; or any combination of these. Most
studies to date have found no overall difference in acute
mortality between patients developing cryptococcal
meningitis prior to initiating ART compared with those
who are ART-experienced [5,10–14]. One limited study
from Botswana including only 26 ART-experienced
participants reported 8% in-hospital mortality among
ART-experienced cryptococcal meningitis patients versus
21% among ART-naı̈ve [13]. However, a subsequent larger
study at the same hospital including 81 other ART-
experienced cryptococcal meningitis patients, found no
difference in acute mortality between ART-experienced
(28%) and ART-naı̈ve individuals (26%). The larger study
found higher 1-year mortality in the ART-experienced
group, possibly indicating ongoing ART treatment failure
or defaulting in this population [14]. However, no such
difference was found during long-term follow-up within
the antifungal combinations for treatment of cryptococcal
meningitis in africa (ACTA) trial [11].
Given the marked heterogeneity in the ART-experienced
population, Rhein et al. in Uganda performed a
secondary analysis of an adjunctive sertraline trial
comparing outcomes among patients who were ART
naı̈ve (n¼ 324), who had initiated, restarted or switched
ART in the last 14 days (n¼ 51), or who had received
ART for over 14 days (n¼ 230) [15]. Although 2-week
mortality was similar between ART-naı̈ve and ART-
experienced patients overall, 2.5-fold higher mortality
was observed among ART-experienced patients who had
initiated ARTwithin the previous 14 days (47% vs. 19% in
patients on ART for 15 days to 6 months, P< 0.01).
These patients likely had subclinical cryptococcal
meningitis when ART was initiated, with early immune
recovery resulting in an exaggerated central nervous
system inflammatory response and fatal unmasking
immune reconstitution inflammatory syndrome (IRIS)
[10,15]. These findings of excess mortality with
unmasking IRIS require further confirmation.
There are currently no data to guide ART management in
ART-experienced cryptococcal patients. In particular,
addressing whether ART should be continued or
temporarily interrupted in patients presenting with
suspected unmasking IRIS, optimal timing and choice
of ARTregimen for re-initiation if withdrawn because of
nonadherence, and when failing ARTregimens should be
switched. In the absence of clear evidence, our pragmatic
consensus-based approach, meant to provide interim
guidance pending controlled trials, is as follows:
1. We recommend that the balance of risks favours
discontinuing ART in patients who are diagnosed with
cryptococcal meningitis within 14 days following ART
initiation as they are likely to have had active cryptococcal
meningitis at ART initiation, and are at high risk of IRIS
(which may potentially be abrogated by discontinuing
ART at this early stage prior to significant immune
reconstitution). The assumption in these cases is that ART
was initiated in the context of active central nervous system
(CNS) infections. Limited evidence to date suggests
increased mortality in these individuals [15]. This includes
patients who have re-initiated ARTor switched regimens
in the previous 14 days. Such patients should then be
managed as ART-naı̈ve individuals, with appropriate ART
re-initiated at 4–6 weeks post initiation of antifungals.
2. ART should be continued in patients reporting good
adherence to ART for 15 days to 6 months. These patients
may be presenting with possible unmasking IRIS or with
CNS cryptococcal infections that have developed after
ART initiation in the context of incomplete immune
recovery. Factors, which favour a diagnosis of unmasking
IRIS are good ART adherence, low viral load, rise in
CD4þ count, and low CSF fungal burden [16]. In all of
these cases, our opinion is that interrupting ART is
unlikely to improve the clinical course of cryptococcal
meningitis as any reversal in the established ART-induced
immune restoration and associated IRIS will take days to
weeks. Furthermore, stopping ART could place patients at
risk for developing drug resistance (if on an non-
nucleoside reverse transcriptase inhibitor [NNRTI]-based
regimen [17] but much less likely if on dolutegravir-based
regimen [18]) and other AIDS-related complications.
3. In patients receiving ART for more than 6 months, the
primary explanation for the development of cryptococcal
meningitis is most likely virologic failure with an
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associated drop in CD4þ count resulting from either sub-
optimal adherence and/or drug resistance, rather than
unmasking IRIS [15]. Another possible explanation is an
immunovirological discordant response to ART,
although this is uncommon. A good adherence history
and prompt viral load measurement could help
discriminate, although accurately assessing adherence is
challenging and unreliable. If point of care or rapid viral
load testing is available and shows viral suppression, we
recommend continuation of ART. In those with
demonstrated virologic failure, or in whom rapid viral
load testing cannot be performed, we advise that ART be
discontinued at meningitis diagnosis. ART-experienced
patients with virologic failure because of poor adherence
may be at similar risk of poor outcomes with rapid ART
re-initiation or improved ART adherence following
cryptococcal meningitis diagnosis as was observed for
ART-naı̈ve patients in the COAT trial [7]. ART
continuation in the context of established drug resistance
could be futile and potentially lead to further resistance. If
discontinued, appropriate ART should be re-introduced
after 4–6 weeks of antifungal therapy, alongside
enhanced adherence counselling. ART regimens should
be chosen based on adherence assessment and genotypic
resistance testing if available, and in line with national
HIV guidelines (for example, switching from first to
second line ART regimen if there has been virological
failure).
4. Patients who have defaulted their ART or are not
adherent, regardless of prior duration of ARTuse, should
be approached as ART-naı̈ve with ART re-initiated after
4–6 weeks of antifungal treatment. The ART regimen
should be selected according to ART history and in line
with national HIV guidelines.
Figure 1 below is an illustration of the suggested
management of antiretroviral therapy-experienced parti-
cipants diagnosed with cryptococcal meningitis.
This clinical approach is not all encompassing, reflecting
difficulties in providing guidance covering every possible
scenario. However, in the absence of detailed recom-
mendations in most national HIV guidelines, we
believe this provides a framework for management in
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Fig. 1. Suggested management of antiretroviral therapy-experienced participants diagnosed with cryptococcal meningitis.
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most ART-experienced cryptococcal meningitis patients.
We acknowledge that many clinicians are understandably
reluctant to discontinue ART but we advocate for
cryptococcal meningitis patients to be approached as
unique cases where withholding ART may be in their
best interest. Further research is required to rigorously
evaluate ART management strategies that aim to
optimize outcomes in ART-experienced cryptococcal
meningitis patients and enable us to move from an
approach based on expert opinion to one underpinned by
a firm evidence base.
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